CN111233810B - Preparation method and application of hydroxycinnamoyl ester type catechin - Google Patents
Preparation method and application of hydroxycinnamoyl ester type catechin Download PDFInfo
- Publication number
- CN111233810B CN111233810B CN202010056390.XA CN202010056390A CN111233810B CN 111233810 B CN111233810 B CN 111233810B CN 202010056390 A CN202010056390 A CN 202010056390A CN 111233810 B CN111233810 B CN 111233810B
- Authority
- CN
- China
- Prior art keywords
- trans
- add
- epigallocatechin
- epicatechin
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 235000005487 catechin Nutrition 0.000 title claims abstract description 38
- -1 hydroxycinnamoyl ester Chemical class 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 title claims abstract description 10
- 229950001002 cianidanol Drugs 0.000 title claims abstract description 9
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims abstract description 81
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims abstract description 63
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 claims abstract description 48
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims abstract description 41
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims abstract description 41
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims abstract description 37
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims abstract description 36
- 235000012734 epicatechin Nutrition 0.000 claims abstract description 36
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims abstract description 36
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940074360 caffeic acid Drugs 0.000 claims abstract description 13
- 235000004883 caffeic acid Nutrition 0.000 claims abstract description 13
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims abstract description 13
- 150000001765 catechin Chemical class 0.000 claims abstract description 11
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims abstract description 5
- 230000021736 acetylation Effects 0.000 claims abstract description 4
- 238000006640 acetylation reaction Methods 0.000 claims abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 168
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 120
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 99
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 40
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 34
- 238000006243 chemical reaction Methods 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 24
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 20
- 238000010898 silica gel chromatography Methods 0.000 claims description 19
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 17
- 239000003208 petroleum Substances 0.000 claims description 17
- 239000007795 chemical reaction product Substances 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 14
- 238000004440 column chromatography Methods 0.000 claims description 13
- 239000000499 gel Substances 0.000 claims description 13
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 12
- COJAJMNJKIUMOT-DUXPYHPUSA-N (e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl chloride Chemical compound OC1=CC=C(\C=C\C(Cl)=O)C=C1O COJAJMNJKIUMOT-DUXPYHPUSA-N 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- VBKNTGMWIPUCRF-UHFFFAOYSA-M potassium;fluoride;hydrofluoride Chemical compound F.[F-].[K+] VBKNTGMWIPUCRF-UHFFFAOYSA-M 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 7
- 239000005695 Ammonium acetate Substances 0.000 claims description 7
- 229940043376 ammonium acetate Drugs 0.000 claims description 7
- 235000019257 ammonium acetate Nutrition 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000002390 rotary evaporation Methods 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 6
- BYHBHNKBISXCEP-QPJJXVBHSA-N 4-acetoxycinnamic acid Chemical compound CC(=O)OC1=CC=C(\C=C\C(O)=O)C=C1 BYHBHNKBISXCEP-QPJJXVBHSA-N 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 229930013783 (-)-epicatechin Natural products 0.000 claims description 2
- 235000007355 (-)-epicatechin Nutrition 0.000 claims description 2
- HKPGWUPXXPIOAN-UHFFFAOYSA-N (-)-epigallocatechin 3-O-p-coumaroate Natural products C1=CC(O)=CC=C1C=CC(=O)OC1C(C=2C=C(O)C(O)=C(O)C=2)OC2=CC(O)=CC(O)=C2C1 HKPGWUPXXPIOAN-UHFFFAOYSA-N 0.000 claims description 2
- BNLVODKLELGOBT-UHFFFAOYSA-N (-)-epigallocatechin 3-O-caffeoate Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 BNLVODKLELGOBT-UHFFFAOYSA-N 0.000 claims description 2
- 229910017435 S2 In Inorganic materials 0.000 claims description 2
- YVHPHQBRUPLYOS-UHFFFAOYSA-N dichloromethane;methane Chemical compound C.ClCCl YVHPHQBRUPLYOS-UHFFFAOYSA-N 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000011698 potassium fluoride Substances 0.000 claims description 2
- 235000003270 potassium fluoride Nutrition 0.000 claims description 2
- 238000006884 silylation reaction Methods 0.000 claims description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 abstract description 10
- 108010028144 alpha-Glucosidases Proteins 0.000 abstract description 10
- 239000003472 antidiabetic agent Substances 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 238000005886 esterification reaction Methods 0.000 abstract description 2
- 125000006239 protecting group Chemical group 0.000 abstract description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 abstract 1
- 239000012346 acetyl chloride Substances 0.000 abstract 1
- 230000032050 esterification Effects 0.000 abstract 1
- 238000002444 silanisation Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 20
- 238000005481 NMR spectroscopy Methods 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 239000000843 powder Substances 0.000 description 10
- 244000269722 Thea sinensis Species 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 5
- WBCMGDNFDRNGGZ-ACNVUDSMSA-N coumarate Natural products COC(=O)C1=CO[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]3[C@@H]1C=C[C@]34OC(=O)C(=C4)[C@H](C)OC(=O)C=Cc5ccc(O)cc5 WBCMGDNFDRNGGZ-ACNVUDSMSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- LVTHXRLARFLXNR-UHFFFAOYSA-M potassium;1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonate Chemical compound [K+].[O-]S(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F LVTHXRLARFLXNR-UHFFFAOYSA-M 0.000 description 4
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 3
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 3
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 3
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 3
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 2
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 2
- UXKLQDCALAWFIU-VKNDCNMPSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-tetradecoxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCCCC)C1=CC=CC=C1 UXKLQDCALAWFIU-VKNDCNMPSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- HPJGEESDHAUUQR-SKGSPYGFSA-N (2s)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-1-[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-2-[[(2s)-3-naphthalen-2-yl-2-(3-pyridin-3-ylpropanoylamino)propanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]buta Chemical compound NC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)CCC=1C=NC=CC=1)CC1=CC=CC=C1 HPJGEESDHAUUQR-SKGSPYGFSA-N 0.000 description 1
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 1
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 1
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 1
- VGNCBRNRHXEODV-XXVHXNRLSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-dodecoxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCC)C1=CC=CC=C1 VGNCBRNRHXEODV-XXVHXNRLSA-N 0.000 description 1
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 description 1
- IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 4-nitrophenyl alpha-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 0.000 description 1
- LDIOUQIXNSSOGU-UHFFFAOYSA-N 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5h-cyclopenta[d]pyrazolo[1,5-a]pyrimidine Chemical compound CC1=NN2C(NC(CC)CC)=C3CCCC3=NC2=C1C1=CC=C(OC)C=C1Cl LDIOUQIXNSSOGU-UHFFFAOYSA-N 0.000 description 1
- DFYRUELUNQRZTB-UHFFFAOYSA-N Acetovanillone Natural products COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- HKPGWUPXXPIOAN-XMTAIGAMSA-N Epigallocatechin 3-O-p-coumarate Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)O[C@H]1[C@@H](C=2C=C(O)C(O)=C(O)C=2)OC2=CC(O)=CC(O)=C2C1 HKPGWUPXXPIOAN-XMTAIGAMSA-N 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- BGXZIBSLBRKDTP-UHFFFAOYSA-N methyl 9-(4-chloroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Cl)C=C1 BGXZIBSLBRKDTP-UHFFFAOYSA-N 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
- C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
技术领域technical field
本发明属于天然药物化学技术领域,具体涉及四种名分别为表儿茶素反式香豆酸酯、表儿茶素反式咖啡酸酯、表没食子儿茶素反式香豆酸酯与表没食子儿茶素反式咖啡酸酯的羟基肉桂酰酯型儿茶素的制备方法和应用。The invention belongs to the technical field of natural medicinal chemistry, and specifically relates to four kinds of drugs named respectively epicatechin trans coumarate, epicatechin trans caffeate, epigallocatechin trans coumarate and epigallocatechin trans coumarate and epigallocatechin The preparation method and application of the hydroxycinnamoyl ester type catechin of gallocatechin trans-caffeate.
背景技术Background technique
茶叶中含有丰富的茶多酚,占茶叶干物质的18%-36%。其中,大部分是儿茶素(黄烷醇类),占茶叶干物质的12%-24%。研究表明,儿茶素是茶叶中重要的滋味物质。而且,儿茶素还具有抗炎、抗氧化、抗癌、心血管和神经保护作用等药理功能。Tea is rich in tea polyphenols, accounting for 18%-36% of the dry matter of tea. Among them, most of them are catechins (flavanols), accounting for 12%-24% of the dry matter of tea leaves. Studies have shown that catechin is an important taste substance in tea. Moreover, catechins also have pharmacological functions such as anti-inflammatory, anti-oxidation, anti-cancer, cardiovascular and neuroprotective effects.
化学合成实验通常都需要特殊的反应条件,反应所使用的药品试剂通常危险性较大。现有技术中公开的这类儿茶素的合成方法复杂,反应条件苛刻,一般实验室的条件满足不了反应要求,无法完成制备。如何在现有制备方法和反应原料中进行筛选,设计出方法简单、条件温和的该四种羟基肉桂酰酯型儿茶素制备方法,具有重要的意义。Chemical synthesis experiments usually require special reaction conditions, and the pharmaceutical reagents used in the reaction are usually more dangerous. The synthesis method of this type of catechin disclosed in the prior art is complicated, and the reaction conditions are harsh, and the conditions of general laboratories cannot meet the reaction requirements, and the preparation cannot be completed. How to screen the existing preparation methods and reaction materials, and design a preparation method of the four hydroxycinnamoyl catechins with simple methods and mild conditions is of great significance.
发明内容Contents of the invention
本发明要解决的技术问题为克服现有技术中的不足之处,提供一种一类羟基肉桂酰酯型儿茶素的制备方法。The technical problem to be solved by the present invention is to overcome the deficiencies in the prior art and provide a preparation method of a class of hydroxycinnamoyl catechins.
本发明要解决的又一个技术问题为提供一种上述方法制备的一类羟基肉桂酰酯型儿茶素对α-葡萄糖苷酶的抑制作用,可应用于制备降血糖药物。Another technical problem to be solved by the present invention is to provide an inhibitory effect of a class of hydroxycinnamoyl ester catechins prepared by the above method on α-glucosidase, which can be applied to the preparation of hypoglycemic drugs.
为解决本发明的技术问题,所提供的技术方案为:In order to solve the technical problems of the present invention, the technical solution provided is:
一类羟基肉桂酰酯型儿茶素的制备方法,该类羟基肉桂酰酯型儿茶素包括4种儿茶素,该4种儿茶素的名称分别为表儿茶素反式香豆酸酯即(–)-epicatechin 3-O-p-coumaroate、表儿茶素反式咖啡酸酯即(–)-epicatechin3-O-caffeoate、表没食子儿茶素反式香豆酸酯即(–)-epigallocatechin3-O-p-coumaroate、表没食子儿茶素反式咖啡酸酯即(–)-epigallocatechin3-O-caffeoate,其结构式分别如式Ⅰ、式Ⅱ、式Ⅲ和式Ⅳ所示,A method for preparing a class of hydroxycinnamoyl ester catechins. The hydroxycinnamoyl ester catechins include 4 kinds of catechins, and the names of the 4 kinds of catechins are respectively epicatechin trans-coumaric acid Ester (–)-epicatechin 3-O-p-coumaroate, Epigallocatechin trans-coumarate (–)-epigallocatechin3 -O-p-coumaroate, epigallocatechin trans-caffeoate (–)-epigallocatechin3-O-caffeoate, the structural formulas are shown in formula Ⅰ, formula Ⅱ, formula Ⅲ and formula Ⅳ respectively,
该类羟基肉桂酰酯型儿茶素的制备方法包括如下步骤:The preparation method of the hydroxycinnamoyl ester type catechin comprises the following steps:
S1、以表儿茶素即EC为原料,通过全乙酰化、脱去酚羟基上的乙酰基、酚羟基硅烷化及脱去3位乙酰基四个反应后制得5,7,3’,4’-O-四叔丁基二甲基硅基-表儿茶素;S1. Using epicatechin (EC) as a raw material, 5,7,3', 4'-O-tetra-tert-butyldimethylsilyl-epicatechin;
以表没食子儿茶素即EGC为原料,通过全乙酰化、脱去酚羟基上的乙酰基、酚羟基硅烷化及脱去3位乙酰基四个反应后制得5,7,3’,4’,5’-O-五叔丁基二甲基硅基-表没食子儿茶素;Using epigallocatechin (EGC) as a raw material, 5,7,3',4 is prepared by four reactions: full acetylation, removal of acetyl group on phenolic hydroxyl group, silylation of phenolic hydroxyl group and removal of 3-position acetyl group. ',5'-O-penta-tert-butyldimethylsilyl-epigallocatechin;
S2、制备3”,4”-O-二乙酰基-5,7,3’,4’-O-四叔丁基二甲基硅基-表儿茶素反式咖啡酸酯;S2. Preparation of 3”, 4”-O-diacetyl-5,7,3’,4’-O-tetra-tert-butyldimethylsilyl-epicatechin trans-caffeate;
称取92.0mg步骤S1制得的5,7,3’,4’-O-四叔丁基二甲基硅基-表儿茶素于25mL圆底烧瓶中,加入0.2mL干燥的吡啶,2.0mL干燥的二氯甲烷,在冰浴条件下缓慢滴加含有0.18mmol的3,4-O-二乙酰化咖啡酰氯的干燥二氯甲烷3.0mL,室温反应过夜,加适量的水和等体积的二氯甲烷萃取三次,二氯甲烷层用无水硫酸钠干燥后浓缩,经硅胶柱层析以石油醚:乙酸乙酯=30:1进行洗脱后得到3”,4”-O-二乙酰基-5,7,3’,4’-O-四叔丁基二甲基硅基-表儿茶素反式咖啡酸酯;Weigh 92.0 mg of 5,7,3',4'-O-tetra-tert-butyldimethylsilyl-epicatechin prepared in step S1 into a 25 mL round bottom flask, add 0.2 mL of dry pyridine, 2.0 mL of dry dichloromethane, slowly add 3.0 mL of dry dichloromethane containing 0.18 mmol of 3,4-O-diacetylated caffeoyl chloride dropwise under ice bath conditions, react overnight at room temperature, add appropriate amount of water and an equal volume of Dichloromethane was extracted three times, and the dichloromethane layer was dried over anhydrous sodium sulfate and concentrated. After silica gel column chromatography was eluted with petroleum ether: ethyl acetate = 30:1 to obtain 3”, 4”-O-diacetyl -5,7,3',4'-O-tetra-tert-butyldimethylsilyl-epicatechin trans-caffeate;
S3、制备4”-O-乙酰基-5,7,3’,4’-O-四叔丁基二甲基硅基-表儿茶素反式香豆酸酯;S3. Preparation of 4"-O-acetyl-5,7,3',4'-O-tetra-tert-butyldimethylsilyl-epicatechin trans-coumarate;
称取395.0mg步骤S1制得的5,7,3’,4’-O-四叔丁基二甲基硅基-表儿茶素于25mL圆底烧瓶中,加入1.5mL干燥的吡啶,3.0mL干燥的二氯甲烷,在冰浴条件下缓慢滴加含有0.80mmol的4-O-乙酰化香豆酰氯的干燥二氯甲烷5.0mL,室温反应过夜,加适量的水和等体积的二氯甲烷萃取三次,二氯甲烷层用无水硫酸钠干燥后浓缩,经硅胶柱层析,以石油醚:乙酸乙酯=50:1进行洗脱后得到4”-O-乙酰基-5,7,3’,4’-O-四叔丁基二甲基硅基-表儿茶素反式香豆酸酯;Weigh 395.0 mg of 5,7,3',4'-O-tetra-tert-butyldimethylsilyl-epicatechin prepared in step S1 into a 25 mL round bottom flask, add 1.5 mL of dry pyridine, 3.0 mL of dry dichloromethane, slowly add 5.0 mL of dry dichloromethane containing 0.80 mmol of 4-O-acetylated coumaryl chloride dropwise under ice bath conditions, react overnight at room temperature, add appropriate amount of water and an equal volume of dichloromethane Methane was extracted three times, the dichloromethane layer was dried over anhydrous sodium sulfate and concentrated, and silica gel column chromatography was eluted with petroleum ether: ethyl acetate = 50:1 to obtain 4”-O-acetyl-5,7 ,3',4'-O-tetra-tert-butyldimethylsilyl-epicatechin trans-coumarate;
S4、制备3”,4”-O-二乙酰基-5,7,3’,4’,5’-O-五叔丁基二甲基硅基-表没食子儿茶素反式咖啡酸酯;S4. Preparation of 3", 4"-O-diacetyl-5,7,3',4',5'-O-penta-tert-butyldimethylsilyl-epigallocatechin trans-caffeate ;
称取500.0mg步骤S1制得的5,7,3’,4’,5’-O-五叔丁基二甲基硅基-表没食子儿茶素于100mL圆底烧瓶中,加入2.0mL干燥的吡啶,5.0mL干燥的二氯甲烷,在冰浴条件下缓慢滴加含有1.9mmol的3,4-O-二乙酰化咖啡酰氯的干燥二氯甲烷8.0mL,室温反应过夜,加适量的水和等体积的二氯甲烷萃取三次,二氯甲烷层用无水硫酸钠干燥后浓缩,经硅胶柱层析以石油醚:乙酸乙酯=30:1进行洗脱后得到3”,4”-O-二乙酰基-5,7,3’,4’,5’-O-五叔丁基二甲基硅基-表没食子儿茶素反式咖啡酸酯;Weigh 500.0mg of 5,7,3',4',5'-O-penta-tert-butyldimethylsilyl-epigallocatechin prepared in step S1 into a 100mL round bottom flask, add 2.0mL to dry Pyridine, 5.0 mL of dry dichloromethane, slowly add 8.0 mL of dry dichloromethane containing 1.9 mmol of 3,4-O-diacetylated caffeoyl chloride dropwise under ice bath conditions, react overnight at room temperature, add appropriate amount of water and an equal volume of dichloromethane for three extractions, the dichloromethane layer was dried over anhydrous sodium sulfate and concentrated, and eluted with petroleum ether: ethyl acetate = 30:1 by silica gel column chromatography to obtain 3”, 4”- O-diacetyl-5,7,3',4',5'-O-penta-tert-butyldimethylsilyl-epigallocatechin trans-caffeate;
S5、制备4”-O-乙酰基-5,7,3’,4’,5’-O-五叔丁基二甲基硅基-表没食子儿茶素反式香豆酸酯;S5. Preparation of 4"-O-acetyl-5,7,3',4',5'-O-penta-tert-butyldimethylsilyl-epigallocatechin trans-coumarate;
称取370.0mg步骤S1制得的5,7,3’,4’,5’-O-五叔丁基二甲基硅基-表没食子儿茶素于100mL圆底烧瓶中,加入2.0mL干燥的吡啶,5.0mL干燥的二氯甲烷,在冰浴条件下缓慢滴加含有1.5mmol的4-O-乙酰化香豆酰氯的干燥二氯甲烷7.0mL,室温反应过夜,加适量的水和等体积的二氯甲烷萃取三次,二氯甲烷层用无水硫酸钠干燥后浓缩,经硅胶柱层析以石油醚:乙酸乙酯=50:1进行洗脱后得到4”-O-乙酰基-5,7,3’,4’,5’-O-五叔丁基二甲基硅基-表没食子儿茶素反式香豆酸酯;Weigh 370.0mg of 5,7,3',4',5'-O-penta-tert-butyldimethylsilyl-epigallocatechin prepared in step S1 into a 100mL round bottom flask, add 2.0mL to dry Pyridine, 5.0 mL of dry dichloromethane, slowly add 7.0 mL of dry dichloromethane containing 1.5 mmol of 4-O-acetylated coumaryl chloride dropwise under ice bath conditions, react overnight at room temperature, add appropriate amount of water and etc. The volume of dichloromethane was extracted three times, the dichloromethane layer was dried with anhydrous sodium sulfate and then concentrated, and 4”-O-acetyl- 5,7,3',4',5'-O-penta-tert-butyldimethylsilyl-epigallocatechin trans-coumarate;
S6、制备表儿茶素反式咖啡酸酯;S6, preparing epicatechin trans-caffeate;
称取164.0mg步骤S2制得的3”,4”-O-二乙酰基-5,7,3’,4’-O-四叔丁基二甲基硅基-表儿茶素反式咖啡酸酯于25mL圆底烧瓶中,加入28.0mg氟氢化钾,再加入6.0mL干燥的甲醇,50℃下反应6小时,反应产物经LH-20凝胶柱层析,以甲醇洗脱后得到表儿茶素反式咖啡酸酯;Weigh 164.0 mg of 3",4"-O-diacetyl-5,7,3',4'-O-tetra-tert-butyldimethylsilyl-epicatechin trans coffee prepared in step S2 In a 25mL round-bottomed flask, add 28.0mg potassium bifluoride, then add 6.0mL dry methanol, and react at 50°C for 6 hours. The reaction product is eluted with methanol to obtain the following table: Catechin trans caffeate;
S7、制备表没食子儿茶素反式咖啡酸酯;S7, preparing epigallocatechin trans-caffeate;
称取60.0mg步骤S4制得的3”,4”-O-二乙酰基-5,7,3’,4’,5’-O-五叔丁基二甲基硅基-表没食子儿茶素反式咖啡酸酯于25mL圆底烧瓶中,加入200.0mg氟氢化钾,再加入5.0mL干燥的甲醇,50℃下反应6小时,反应产物经LH-20凝胶柱层析,以甲醇洗脱后得到表没食子儿茶素反式咖啡酸酯;Weigh 60.0 mg of 3",4"-O-diacetyl-5,7,3',4',5'-O-penta-tert-butyldimethylsilyl-epigallocatechin prepared in step S4 Add 200.0mg of potassium bifluoride to a 25mL round bottom flask, then add 5.0mL of dry methanol, and react at 50°C for 6 hours. The reaction product is subjected to LH-20 gel column chromatography and washed with methanol. After taking off, epigallocatechin trans-caffeate is obtained;
S8、制备表儿茶素反式香豆酸酯;S8, preparing epicatechin trans-coumarate;
称取163.0mg步骤S3制得的4”-O-乙酰基-5,7,3’,4’-O-四叔丁基二甲基硅基-表儿茶素反式香豆酸酯于25mL圆底烧瓶中,加入136.0mg氟氢化钾,再加入6.0mL干燥的甲醇,室温下反应3.5小时,待反应结束后加入适量的水,用等体积的乙酸乙酯萃取三次,乙酸乙酯层用无水硫酸钠干燥后浓缩,经硅胶柱层析以石油醚:乙酸乙酯=1:1进行洗脱后得到4”-O-乙酰基-表儿茶素反式香豆酸酯;Weigh 163.0 mg of 4"-O-acetyl-5,7,3',4'-O-tetra-tert-butyldimethylsilyl-epicatechin trans-coumarate prepared in step S3 in In a 25mL round bottom flask, add 136.0mg potassium bifluoride, then add 6.0mL dry methanol, react at room temperature for 3.5 hours, add an appropriate amount of water after the reaction is completed, extract three times with an equal volume of ethyl acetate, and the ethyl acetate layer After drying with anhydrous sodium sulfate and concentrating, 4"-O-acetyl-epicatechin trans-coumarate was obtained after silica gel column chromatography was eluted with petroleum ether: ethyl acetate = 1:1;
称取50.0mg的4”-O-乙酰基-表儿茶素反式香豆酸酯于10mL圆底烧瓶中,加450.0mg醋酸铵,加入体积分数为80%甲醇水溶液2.0mL,室温反应5.5小时,反应产物经LH-20凝胶柱层析,以甲醇洗脱后得到表儿茶素反式香豆酸酯;Weigh 50.0 mg of 4”-O-acetyl-epicatechin trans-coumarate into a 10 mL round bottom flask, add 450.0 mg of ammonium acetate, add 2.0 mL of 80% methanol aqueous solution, and react at room temperature for 5.5 hour, the reaction product was subjected to LH-20 gel column chromatography, and was eluted with methanol to obtain epicatechin trans-coumarate;
S9、制备表没食子儿茶素反式香豆酸酯;S9, preparing epigallocatechin trans-coumarate;
称取130.0mg步骤S5制得的4”-O-乙酰基-5,7,3’,4’,5’-O-五叔丁基二甲基硅基-表没食子儿茶素反式香豆酸酯于25mL圆底烧瓶中,加入476.0mg氟氢化钾,再加入8.0mL干燥的甲醇,50℃下反应6小时,反应产物浓缩后经LH-20凝胶柱层析,以甲醇洗脱后得到4”-O-乙酰基-表没食子儿茶素反式香豆酸酯;Weigh 130.0 mg of 4"-O-acetyl-5,7,3',4',5'-O-penta-tert-butyldimethylsilyl-epigallocatechin trans-aroma prepared in step S5 Add 476.0mg of potassium fluoride to a 25mL round-bottomed flask, then add 8.0mL of dry methanol, and react at 50°C for 6 hours. The reaction product is concentrated and eluted with methanol through LH-20 gel column chromatography Finally, 4"-O-acetyl-epigallocatechin trans-coumarate was obtained;
称取36.0mg的4”-O-乙酰基-表没食子儿茶素反式香豆酸酯于10mL圆底烧瓶中,加460.0mg醋酸铵,加入体积分数为80%甲醇水溶液2.0mL,室温反应5小时,反应产物经LH-20凝胶柱层析,以甲醇洗脱后得到表没食子儿茶素反式香豆酸酯;Weigh 36.0mg of 4”-O-acetyl-epigallocatechin trans-coumarate into a 10mL round bottom flask, add 460.0mg of ammonium acetate, add 2.0mL of 80% methanol aqueous solution, and react at room temperature After 5 hours, the reaction product was subjected to LH-20 gel column chromatography and eluted with methanol to obtain epigallocatechin trans-coumarate;
其中步骤S2、S3、S4、S5不分先后顺序,步骤S6、S7、S8、S9不分先后顺序。The steps S2, S3, S4, and S5 are in no particular order, and the steps S6, S7, S8, and S9 are in no particular order.
作为一类羟基肉桂酰酯型儿茶素的制备方法的进一步改进,As a further improvement of the preparation method of a class of hydroxycinnamoyl ester catechins,
优选的,步骤S2中所述的3,4-O-二乙酰化咖啡酰氯通过以下方式制得:Preferably, the 3,4-O-diacetylated caffeoyl chloride described in step S2 is prepared in the following manner:
称取180.1mg咖啡酸于25mL圆底烧瓶中,加入0.3mL干燥的吡啶,0.5mL醋酸酐,在干燥管保护下室温搅拌过夜。待反应结束后,加入水终止反应,经旋转蒸干后即可得到乙酰化咖啡酸即3,4-O-二乙酰化咖啡酸;将反应后的乙酰化咖啡酸转至50mL圆底烧瓶中,加入10mL亚硫酰氯,于90℃加热回流3小时即可得到粗品3,4-O-二乙酰化咖啡酰氯,保存备用。Weigh 180.1 mg of caffeic acid into a 25 mL round bottom flask, add 0.3 mL of dry pyridine and 0.5 mL of acetic anhydride, and stir overnight at room temperature under the protection of a drying tube. After the reaction is finished, add water to terminate the reaction, and then 3,4-O-diacetylated caffeic acid can be obtained after rotary evaporation to dryness; transfer the reacted acetylated caffeic acid to a 50mL round bottom flask , add 10 mL of thionyl chloride, and heat to reflux at 90°C for 3 hours to obtain crude 3,4-O-diacetylated caffeoyl chloride, which is stored for future use.
优选的,步骤S3中所述的4-O-乙酰化香豆酰氯通过以下方式制得:Preferably, the 4-O-acetylated coumaryl chloride described in step S3 is prepared in the following manner:
称取656.0mg香豆酸于25mL圆底烧瓶中,加入0.8mL干燥的吡啶,1.0mL醋酸酐,在干燥管保护下室温搅拌过夜。待反应结束后,加入水终止反应,经旋转蒸干后即可得到乙酰化香豆酸;将反应后的乙酰化香豆酸转至25mL圆底烧瓶中,加入3.0mL亚硫酰氯,于90℃加热回流3小时即可得到粗品4-O-乙酰化香豆酰氯,保存备用。Weigh 656.0 mg of coumaric acid into a 25 mL round bottom flask, add 0.8 mL of dry pyridine and 1.0 mL of acetic anhydride, and stir overnight at room temperature under the protection of a drying tube. After the reaction is finished, add water to terminate the reaction, and then obtain acetylated coumaric acid after rotary evaporation; transfer the reacted acetylated coumaric acid to a 25mL round-bottomed flask, add 3.0mL of thionyl chloride, and dissolve at 90 The crude product 4-O-acetylated coumaroyl chloride can be obtained by heating at reflux at ℃ for 3 hours, which is stored for future use.
为解决本发明的又一个技术问题,所提供的又一个技术方案为,采用上述制备方法制得的一类羟基肉桂酰酯型儿茶素在制备降血糖药物上的用途。In order to solve another technical problem of the present invention, another technical solution provided is the use of a class of hydroxycinnamoyl ester catechins prepared by the above-mentioned preparation method in the preparation of hypoglycemic drugs.
作为一类羟基肉桂酰酯型儿茶素在制备降血糖药物上的用途的进一步改进,所述降血糖药物包括口服型和注射型,所述口服型包括片剂、胶囊剂、颗粒剂、滴丸剂,所述注射型包括注射液、混旋液。As a further improvement of the use of a class of hydroxycinnamoyl ester catechins in the preparation of hypoglycemic drugs, the hypoglycemic drugs include oral and injection types, and the oral types include tablets, capsules, granules, drops, etc. Pills, the injection type includes injection and suspension.
本发明相比现有技术的有益效果在于:The beneficial effect of the present invention compared with prior art is:
1)本发明提供了四种羟基肉桂酰酯型儿茶素的合成方法,与现有技术的合成方法不同,本合成实验所采用的羟基保护基团、酯化反应条件以及对保护基团的水解条件等具有明显的优势,该制备方法简单,条件温和,容易实施,成本较低,具有非常好的应用前景1) The present invention provides the synthetic method of four kinds of hydroxycinnamoyl ester type catechins, different from the synthetic method of prior art, the hydroxyl protecting group that this synthetic experiment adopts, esterification reaction condition and to protecting group The hydrolysis conditions have obvious advantages, the preparation method is simple, the conditions are mild, easy to implement, the cost is low, and it has very good application prospects
2)本发明制备的四种羟基肉桂酰酯型儿茶素具有医学活性,对α-葡萄糖苷酶活性有一定抑制作用,可以用于制备口服型和注射型的降血糖药物,对农业和医药领域具有重要的意义。2) The four hydroxycinnamoyl ester catechins prepared by the present invention have medical activity, and have a certain inhibitory effect on α-glucosidase activity, and can be used to prepare oral and injection hypoglycemic drugs, which are beneficial to agriculture and medicine. field is of great importance.
附图说明Description of drawings
图1为四种羟基肉桂酰酯型儿茶素的合成路径;Fig. 1 is the synthetic route of four kinds of hydroxycinnamoyl ester type catechins;
附图中标记的含义如下:The meanings of the marks in the accompanying drawings are as follows:
1a、3,5,7,3’,4’-O-五乙酰基-表儿茶素1a, 3,5,7,3’,4’-O-pentaacetyl-epicatechin
1b、3,5,7,3’,4’,5’-O-六乙酰基-表没食子儿茶素1b, 3,5,7,3',4',5'-O-hexaacetyl-epigallocatechin
2a、3-O-乙酰基-表儿茶素2a, 3-O-acetyl-epicatechin
2b、3-O-乙酰基-表没食子儿茶素2b, 3-O-acetyl-epigallocatechin
3a、3-O-乙酰基-5,7,3’,4’-O-四叔丁基二甲基硅基-表儿茶素3a, 3-O-acetyl-5,7,3’,4’-O-tetra-tert-butyldimethylsilyl-epicatechin
3b、3-O-乙酰基-5,7,3’,4’,5’-O-五叔丁基二甲基硅基-表没食子儿茶素3b, 3-O-acetyl-5,7,3’,4’,5’-O-penta-tert-butyldimethylsilyl-epigallocatechin
4a、5,7,3’,4’-O-四叔丁基二甲基硅基-表儿茶素4a, 5,7,3',4'-O-tetra-tert-butyldimethylsilyl-epicatechin
4b、5,7,3’,4’,5’-O-五叔丁基二甲基硅基-表没食子儿茶素4b, 5,7,3',4',5'-O-penta-tert-butyldimethylsilyl-epigallocatechin
5a、3,4-O-二乙酰化咖啡酰氯5a, 3,4-O-diacetylated caffeoyl chloride
5b、4-O-乙酰化香豆酰氯5b, 4-O-acetylated coumaryl chloride
6a、3”,4”-O-二乙酰基-5,7,3’,4’-O-四叔丁基二甲基硅基-表儿茶素反式咖啡酸酯6a, 3”, 4”-O-diacetyl-5,7,3’,4’-O-tetra-tert-butyldimethylsilyl-epicatechin trans-caffeate
6b、4”-O-乙酰基-5,7,3’,4’-O-四叔丁基二甲基硅基-表儿茶素反式香豆酸酯6b, 4”-O-acetyl-5,7,3’,4’-O-tetra-tert-butyldimethylsilyl-epicatechin trans-coumarate
6c、3”,4”-O-二乙酰基-5,7,3’,4’,5’-O-五叔丁基二甲基硅基-表没食子儿茶素反式咖啡酸酯6c, 3”, 4”-O-diacetyl-5,7,3’,4’,5’-O-penta-tert-butyldimethylsilyl-epigallocatechin trans-caffeate
6d、4”-O-乙酰基-5,7,3’,4’,5’-O-五叔丁基二甲基硅基-表没食子儿茶素反式香豆酸酯6d, 4"-O-acetyl-5,7,3',4',5'-O-penta-tert-butyldimethylsilyl-epigallocatechin trans-coumarate
7a、4”-O-乙酰基-表儿茶素反式香豆酸酯7a, 4"-O-acetyl-epicatechin trans-coumarate
7b、4”-O-乙酰基-表没食子儿茶素反式香豆酸酯7b, 4”-O-acetyl-epigallocatechin trans-coumarate
8a、表儿茶素反式咖啡酸酯8a, epicatechin trans caffeate
8b、表儿茶素反式香豆酸酯8b, epicatechin trans-coumarate
8c、表没食子儿茶素反式咖啡酸酯8c, epigallocatechin trans caffeate
8d、表没食子儿茶素反式香豆酸酯8d. Epigallocatechin trans-coumarate
具体实施方式Detailed ways
下面结合实施例对本发明作进一步描述:The present invention will be further described below in conjunction with embodiment:
本部分对本发明实验中所使用到的材料以及实验方法进行一般性的描述。虽然为实现本发明目的所使用的许多材料和操作方法是本领域公知的,但是本发明在此作尽可能详细描述。本领域技术人员清楚,在下文中,如果未特别说明,本发明所用材料、设备和操作方法是本领域公知的。This section generally describes the materials and experimental methods used in the experiments of the present invention. While many of the materials and manipulations which are employed for the purposes of the invention are well known in the art, the invention has been described here in as much detail as possible. It will be clear to those skilled in the art that in the following, unless otherwise specified, the materials, equipment and operation methods used in the present invention are well known in the art.
实施例1Example 1
表儿茶素反式香豆酸酯、表儿茶素反式咖啡酸酯、表没食子儿茶素反式香豆酸酯与表没食子儿茶素反式咖啡酸酯的羟基肉桂酰酯型儿茶素的制备;Epigallocatechin transcoumarate, epicatechin transcaffeate, epigallocatechin transcoumarate and epigallocatechin transcaffeate hydroxycinnamoyl ester type The preparation of tea;
1.1仪器与试剂1.1 Instruments and reagents
1H核磁共振谱采用Agilent DD2600 MHz核磁共振仪;质谱采用Agilent6465UPLC-Q-TOF-MS。 1 H nuclear magnetic resonance spectrum adopts Agilent DD2600 MHz nuclear magnetic resonance instrument; mass spectrometry adopts Agilent6465UPLC-Q-TOF-MS.
表儿茶素(EC)和表没食子儿茶素(EGC)分别购买于成都生物制药有限公司和湖北巨胜科技有限公司;咖啡酸和对香豆酸购买于安耐吉化学;其它试剂均为国产分析纯。Epicatechin (EC) and epigallocatechin (EGC) were purchased from Chengdu Biopharmaceutical Co., Ltd. and Hubei Jusheng Technology Co., Ltd.; caffeic acid and p-coumaric acid were purchased from Anaiji Chemical; other reagents were Domestic analytically pure.
1.2表儿茶素反式香豆酸酯、表儿茶素反式咖啡酸酯、表没食子儿茶素反式香豆酸酯与表儿茶素反式咖啡酸酯的羟基肉桂酰酯型儿茶素的合成路线如图1所示;1.2 Epicatechin trans-coumarate, epicatechin trans-caffeate, epigallocatechin trans-coumarate and epicatechin trans-caffeate hydroxycinnamoyl esters The synthetic route of tea element is as shown in Figure 1;
1.3具体实施方法:1.3 Specific implementation methods:
化合物1a的合成:Synthesis of
称取1.16g(4.0mmol)表儿茶素(EC)于50mL圆底烧瓶中,加入6.0mL干燥的吡啶,8.0mL醋酸酐(84.6mmol),在干燥管保护下室温搅拌过夜。待反应结束后,加入水终止反应,经旋转蒸干后即可得到EC全乙酰化产物3,5,7,3’,4’-O-五乙酰基-表儿茶素(1a,1.9g,白色粉末,收率95%)。1H NMR(600MHz,CDCl3):7.33(1H,s),7.25(1H,d,J=8.4Hz),7.18(1H,d,J=8.4Hz),6.65(1H,br s),6.55(1H,br s),5.37(1H,br s),5.09(1H,s),2.95(1H,dd,J=18.0,4.2Hz),2.87(1H,br d,J=18.0Hz),2.27(9H,s),2.26(3H,s),1.90(3H,s)。Weigh 1.16g (4.0mmol) of epicatechin (EC) into a 50mL round bottom flask, add 6.0mL of dry pyridine and 8.0mL of acetic anhydride (84.6mmol), and stir overnight at room temperature under the protection of a drying tube. After the reaction was completed, water was added to terminate the reaction, and the EC peracetylated product 3,5,7,3',4'-O-pentaacetyl-epicatechin (1a, 1.9g , white powder, yield 95%). 1 H NMR (600MHz, CDCl 3 ): 7.33 (1H, s), 7.25 (1H, d, J = 8.4Hz), 7.18 (1H, d, J = 8.4Hz), 6.65 (1H, br s), 6.55 (1H,br s),5.37(1H,br s),5.09(1H,s),2.95(1H,dd,J=18.0,4.2Hz),2.87(1H,br d,J=18.0Hz),2.27 (9H,s),2.26(3H,s),1.90(3H,s).
化合物1b的合成:Synthesis of
称取1.2g(3.9mmol)表没食子儿茶素(EGC)于50mL圆底烧瓶中,加入6.0mL干燥的吡啶,10.0mL醋酸酐(105.7mmol),在干燥管保护下室温搅拌过夜。待反应结束后,加入水终止反应,经旋转蒸干后即可得到EGC全乙酰化产物:3,5,7,3’,4’,5’-O-六乙酰基-表没食子儿茶素(1b,2.1g,白色粉末,收率94%)。1H NMR(600MHz,CDCl3):7.20(2H,s),6.65(1H,brs),6.55(1H,br s),5.36(1H,br s),5.07(1H,s),2.94(1H,dd,J=18.0,4.2Hz),2.88(1H,br d,J=17.4Hz),2.25-2.28(15H,m),1.92(3H,s)。Weigh 1.2g (3.9mmol) of epigallocatechin (EGC) into a 50mL round bottom flask, add 6.0mL of dry pyridine, 10.0mL of acetic anhydride (105.7mmol), and stir overnight at room temperature under the protection of a drying tube. After the reaction is finished, add water to terminate the reaction, and after rotary evaporation to dryness, the EGC peracetylated product can be obtained: 3,5,7,3',4',5'-O-hexaacetyl-epigallocatechin (1b, 2.1g, white powder, yield 94%). 1 H NMR (600MHz, CDCl 3 ): 7.20(2H,s), 6.65(1H,brs), 6.55(1H,brs), 5.36(1H,brs), 5.07(1H,s), 2.94(1H , dd, J = 18.0, 4.2Hz), 2.88 (1H, br d, J = 17.4Hz), 2.25-2.28 (15H, m), 1.92 (3H, s).
化合物2a的合成:Synthesis of
称取500.0mg(1.0mmol)化合物1a于100mL圆底烧瓶中,加入80%甲醇水溶液50mL,7.8g(101.2mmol)醋酸铵,室温搅拌过夜。待反应结束后,加入适量的水,经旋转浓缩去除甲醇,用等体积的乙酸乙酯萃取三次,浓缩乙酸乙酯层,经硅胶柱层析,以乙酸乙酯:甲醇=20:1进行洗脱后得到化合物3-O-乙酰基-表儿茶素(2a,259.0mg,白色粉末,收率78%)。1HNMR(600MHz,DMSO-d6):9.29(1H,s),9.02(1H,s),8.92(1H,s),8.83(1H,s),6.83(1H,s),6.69(1H,d,J=8.4Hz),6.65(1H,d,J=7.8Hz),5.93(1H,s),5.76(1H,s),5.23(1H,br s),4.93(1H,s),2.87(1H,dd,J=17.4,4.2Hz),2.58(1H,br d,J=16.8Hz),1.87(3H,s)。Weigh 500.0mg (1.0mmol) of
化合物2b的合成:Synthesis of
称取4.2g(1.0mol)化合物1b于500mL圆底烧瓶中,加入80%甲醇水溶液80mL,1.0g(11.9mmol)碳酸氢钠,室温搅拌过夜。待反应结束后,加入适量的水,用等体积的乙酸乙酯萃取三次,浓缩乙酸乙酯层,经硅胶柱层析,以乙酸乙酯:甲醇=1:1进行洗脱后得到化合物3-O-乙酰基-表没食子儿茶素(2b,1.05mg,白色粉末,收率40%)。1H NMR(600MHz,DMSO-d6):9.25(1H,s),8.99(1H,s),8.78(1H,s),7.99(1H,s),6.35(2H,s),5.92(1H,d,J=1.2Hz),5.75(1H,d,J=1.8Hz),5.21(1H,br s),4.85(1H,s),2.87(1H,dd,J=17.4,4.8Hz),2.57(1H,br d,J=16.8Hz),1.88(3H,s)。Weigh 4.2g (1.0mol) of
化合物3a的合成:Synthesis of compound 3a:
称取200.0mg(0.6mmol)化合物2a于100mL圆底烧瓶中,加入干燥的二氯甲烷10mL,816.0mg(12.0mmol)咪唑,40mg(0.33mmol)4-二甲氨基吡啶,在冰浴条件下缓慢滴加含有723.4mg(4.8mmol)叔丁基二甲基氯硅烷的干燥的二氯甲烷溶液10mL。室温搅拌过夜。待反应结束后,加入适量的水,用等体积的二氯甲烷萃取三次,二氯甲烷层溶液用饱和氯化钠洗涤后浓缩,经硅胶柱层析,以石油醚:乙酸乙酯=100:1进行洗脱后得到化合物3-O-乙酰基-5,7,3’,4’-O-四叔丁基二甲基硅基-表儿茶素(3a,450.0mg,透明油状,收率95%)。1H NMR(600MHz,CDCl3):6.87(1H,s),6.85(1H,d,J=8.4Hz),6.79(1H,d,J=7.8Hz),6.13(1H,brs),5.96(1H,br s),5.37(1H,br s),4.94(1H,s),2.90(1H,dd,J=17.4,4.2Hz),2.83(1H,br d,J=18.0Hz),1.87(3H,s),0.94-0.98(36H,m),0.15-0.21(24H,m)。Weigh 200.0mg (0.6mmol) of
化合物3b的合成:Synthesis of
称取500.0mg(1.4mmol)化合物2b于100mL圆底烧瓶中,加入干燥的二氯甲烷10mL,2.4g(35.3mmol)咪唑,100mg(0.82mmol)4-二甲氨基吡啶,在冰浴条件下缓慢滴加含有2.4g(16.0mmol)叔丁基二甲基氯硅烷的干燥的二氯甲烷溶液10mL。室温搅拌过夜。待反应结束后,加入适量的水,用等体积的二氯甲烷萃取三次,二氯甲烷层溶液用饱和氯化钠洗涤后浓缩,经硅胶柱层析,以石油醚:乙酸乙酯=200:1进行洗脱后得到化合物3-O-乙酰基-5,7,3’,4’,5’-O-五叔丁基二甲基硅基-表没食子儿茶素(3b,970.0mg,透明油状,收率74%)。1HNMR(600MHz,CDCl3):6.55(2H,s),6.11(1H,d,J=2.4Hz),5.95(1H,d,J=2.4Hz),5.36(1H,m),4.91(1H,br s),2.89(1H,dd,J=17.4,4.8Hz),2.81(1H,dd,J=17.4,3.0Hz),1.86(3H,s),0.90-0.97(45H,m),0.08-0.21(30H,m)。Weigh 500.0mg (1.4mmol) of
化合物4a的合成:Synthesis of
称取100.0mg(0.13mmol)化合物3a于50mL圆底烧瓶中,用100uL干燥的二氯甲烷溶解,再加入干燥的甲醇10mL,50.0mg(0.36mmol)碳酸钾,室温搅拌2小时。待反应结束后,加入适量的水,用等体积的乙酸乙酯萃取三次,乙酸乙酯层溶液用无水硫酸钠干燥并浓缩,经硅胶柱层析,以石油醚:乙酸乙酯=100:1进行洗脱后得到化合物5,7,3’,4’-O-四叔丁基二甲基硅基-表儿茶素(4a,38.0mg,透明油状,收率40%)。1H NMR(600MHz,CDCl3):6.94(1H,d,J=1.8Hz),6.92(1H,dd,J=8.4,1.8Hz),6.84(1H,d,J=7.8Hz),6.11(1H,d,J=2.4Hz),5.96(1H,d,J=1.8Hz),4.86(1H,s),4.20(1H,br s),2.86(1H,s),2.85(1H,s),0.99(9H,s),0.97(9H,s),0.96(9H,s),0.95(9H,s),0.16-0.22(24H,m)。Weigh 100.0mg (0.13mmol) of compound 3a into a 50mL round bottom flask, dissolve it in 100uL of dry dichloromethane, then add 10mL of dry methanol, 50.0mg (0.36mmol) of potassium carbonate, and stir at room temperature for 2 hours. After the reaction is finished, add an appropriate amount of water, extract three times with an equal volume of ethyl acetate, dry the ethyl acetate layer solution with anhydrous sodium sulfate and concentrate, and perform silica gel column chromatography with petroleum ether:ethyl acetate=100: 1 was eluted to obtain compound 5,7,3',4'-O-tetra-tert-butyldimethylsilyl-epicatechin (4a, 38.0 mg, transparent oil, yield 40%). 1 H NMR (600MHz, CDCl 3 ): 6.94 (1H, d, J = 1.8Hz), 6.92 (1H, dd, J = 8.4, 1.8Hz), 6.84 (1H, d, J = 7.8Hz), 6.11 ( 1H,d,J=2.4Hz),5.96(1H,d,J=1.8Hz),4.86(1H,s),4.20(1H,br s),2.86(1H,s),2.85(1H,s) ,0.99(9H,s),0.97(9H,s),0.96(9H,s),0.95(9H,s),0.16-0.22(24H,m).
化合物4b的合成:Synthesis of
称取970.0mg(1.06mmol)化合物3b于100mL圆底烧瓶中,用100uL干燥的二氯甲烷溶解,再加入干燥的甲醇40mL,200mg(1.44mmol)碳酸钾,室温搅拌2小时。待反应结束后,加入适量的水,用等体积的乙酸乙酯萃取三次,乙酸乙酯层溶液用无水硫酸钠干燥并浓缩,经硅胶柱层析,以石油醚:乙酸乙酯=200:1进行洗脱后得到化合物5,7,3’,4’,5’-O-五叔丁基二甲基硅基-表没食子儿茶素(4b,353.0mg,透明油状,收率38%)。1H NMR(600MHz,CDCl3):6.59(2H,s),6.09(1H,d,J=1.8Hz),5.95(1H,d,J=2.4Hz),4.82(1H,br s),4.16(1H,m),3.47(1H,s),2.85(1H,dd,J=16.8,4.2Hz),2.80(1H,dd,J=16.8,3.0Hz),0.90-0.99(45H,m),0.10-0.22(30H,m)。Weigh 970.0mg (1.06mmol) of
化合物5a的合成:Synthesis of
称取180.1mg(1.0mmol)咖啡酸于25mL圆底烧瓶中,加入0.3mL干燥的吡啶,0.5mL醋酸酐(5.3mmol),在干燥管保护下室温搅拌过夜。待反应结束后,加入水终止反应,经旋转蒸干后即可得到乙酰化咖啡酸(3,4-O-二乙酰化咖啡酸,250.8mg,收率95%)。1H NMR(600MHz,DMSO-d6):12.47(1H,s)7.66(1H,s),7.63(1H,d,J=8.4Hz),7.57(1H,d,J=16.2Hz),7.31(1H,d,J=8.4Hz),6.53(1H,d,J=16.2Hz),2.29(3H,s),2.29(3H,s)。将反应后的乙酰化咖啡酸转至50mL圆底烧瓶中,加入10mL亚硫酰氯,于90℃加热回流3小时即可得到粗品化合物3,4-O-二乙酰化咖啡酰氯(5a),直接用于下一步反应。Weigh 180.1 mg (1.0 mmol) of caffeic acid into a 25 mL round bottom flask, add 0.3 mL of dry pyridine and 0.5 mL of acetic anhydride (5.3 mmol), and stir overnight at room temperature under the protection of a drying tube. After the reaction was completed, water was added to terminate the reaction, and acetylated caffeic acid (3,4-O-diacetylated caffeic acid, 250.8 mg, yield 95%) was obtained after rotary evaporation to dryness. 1 H NMR (600MHz, DMSO-d 6 ): 12.47 (1H, s) 7.66 (1H, s), 7.63 (1H, d, J = 8.4Hz), 7.57 (1H, d, J = 16.2Hz), 7.31 (1H,d,J=8.4Hz), 6.53(1H,d,J=16.2Hz), 2.29(3H,s), 2.29(3H,s). Transfer the reacted acetylated caffeic acid to a 50 mL round bottom flask, add 10 mL of thionyl chloride, and heat to reflux at 90° C. for 3 hours to obtain the crude compound 3,4-O-diacetylated caffeoyl chloride (5a), directly for the next reaction.
化合物5b的合成:Synthesis of
称取656.0mg(4.0mmol)咖啡酸于25mL圆底烧瓶中,加入0.8mL干燥的吡啶,1.0mL醋酸酐(10.6mmol),在干燥管保护下室温搅拌过夜。待反应结束后,加入水终止反应,经旋转蒸干后即可得到乙酰化香豆酸(4-O-乙酰化香豆酸,774.6mg,收率94%)。1H NMR(600MHz,DMSO-d6):12.36(1H,s)7.73(2H,d,J=9.0Hz),7.60(1H,d,J=14.4Hz),7.18(2H,d,J=8.4Hz),6.50(1H,d,J=16.2Hz),2.28(3H,s)。将反应后的乙酰化香豆酸(251.0mg,1.2mmol)转至25mL圆底烧瓶中,加入3.0mL亚硫酰氯,于90℃加热回流3小时即可得到粗品化合物4-O-乙酰化香豆酰氯(5b),直接用于下一步反应。Weigh 656.0 mg (4.0 mmol) of caffeic acid into a 25 mL round bottom flask, add 0.8 mL of dry pyridine and 1.0 mL of acetic anhydride (10.6 mmol), and stir overnight at room temperature under the protection of a drying tube. After the reaction was completed, water was added to terminate the reaction, and acetylated coumaric acid (4-O-acetylated coumaric acid, 774.6 mg, yield 94%) was obtained after rotary evaporation to dryness. 1 H NMR (600MHz, DMSO-d 6 ): 12.36 (1H, s) 7.73 (2H, d, J = 9.0Hz), 7.60 (1H, d, J = 14.4Hz), 7.18 (2H, d, J = 14.4Hz), 7.18 (2H, d, J = 8.4Hz), 6.50 (1H, d, J = 16.2Hz), 2.28 (3H, s). The reacted acetylated coumaric acid (251.0 mg, 1.2 mmol) was transferred to a 25 mL round bottom flask, 3.0 mL of thionyl chloride was added, and heated to reflux at 90° C. for 3 hours to obtain the crude compound 4-O-acetylated coumaric acid Soybean acid chloride (5b) was directly used in the next reaction.
化合物6a的合成:Synthesis of
称取化合物4a(92.0mg,0.12mmol)于25mL圆底烧瓶中,加入0.2mL干燥的吡啶,2.0mL干燥的二氯甲烷,在冰浴条件下缓慢滴加含有化合物5a(0.18mmol)的干燥二氯甲烷3.0mL。室温反应过夜,加适量的水和等体积的二氯甲烷萃取三次,二氯甲烷层用无水硫酸钠干燥后浓缩,经硅胶柱层析以石油醚:乙酸乙酯=30:1进行洗脱后得到化合物3”,4”-O-二乙酰基-5,7,3’,4’-O-四叔丁基二甲基硅基-表儿茶素反式咖啡酸酯(6a,95.5mg,油状,收率78%)。1H NMR(600MHz,CDCl3):7.45(1H,d,J=15.6Hz),7.32(1H,dd,J=8.4,1.2Hz),7.26(1H,br s),7.16(1H,d,J=8.4Hz),6.89(1H,d,J=1.8Hz),6.87(1H,br d,J=8.4Hz),6.77(1H,d,J=8.4Hz),6.26(1H,d,J=16.2Hz),6.15(1H,d,J=2.4Hz),5.96(1H,d,J=1.8Hz),5.50(1H,br s),5.00(1H,s),2.96(1H,dd,J=18,4.8Hz),2.90(1H,br d,J=17.4Hz),2.27(6H,s),0.92-0.97(36H,m),0.12-0.21(24H,m)。Weigh
化合物6b的合成:Synthesis of
称取化合物4a(395.0mg,0.53mmol)于25mL圆底烧瓶中,加入1.5mL干燥的吡啶,3.0mL干燥的二氯甲烷,在冰浴条件下缓慢滴加含有化合物5b(0.80mmol)的干燥二氯甲烷5.0mL。室温反应过夜,加适量的水和等体积的二氯甲烷萃取三次,二氯甲烷层用无水硫酸钠干燥后浓缩,经硅胶柱层析,以石油醚:乙酸乙酯=50:1进行洗脱后得到化合物4”-O-乙酰基-5,7,3’,4’-O-四叔丁基二甲基硅基-表儿茶素反式香豆酸酯(6b,197.8mg,油状,收率40%)。1H NMR(600MHz,CDCl3):7.49(1H,d,J=15.6Hz),7.44(2H,d,J=9.0Hz),7.07(1H,d,J=9.0Hz),6.91(1H,d,J=1.8Hz),6.86(1H,dd,J=8.4,2.4Hz),6.77(1H,d,J=8.4Hz),6.26(1H,d,J=16.2Hz),6.16(1H,d,J=1.8Hz),5.97(1H,d,J=2.4Hz),5.52(1H,br s),5.01(1H,s),2.97(1H,dd,J=17.4,4.2Hz),2.90(1H,dd,J=16.8,3.0Hz),2.28(3H,s),0.92-0.97(36H,m),0.12-0.21(24H,m)。Weigh
化合物6c的合成:Synthesis of
称取化合物4b(500.0mg,0.57mmol)于100mL圆底烧瓶中,加入2.0mL干燥的吡啶,5.0mL干燥的二氯甲烷,在冰浴条件下缓慢滴加含有化合物5a(1.9mmol)的干燥二氯甲烷8.0mL。室温反应过夜,加适量的水和等体积的二氯甲烷萃取三次,二氯甲烷层用无水硫酸钠干燥后浓缩,经硅胶柱层析以石油醚:乙酸乙酯=30:1进行洗脱后得到化合物3”,4”-O-二乙酰基-5,7,3’,4’,5’-O-五叔丁基二甲基硅基-表没食子儿茶素反式咖啡酸酯(6c,172.1mg,油状,收率70%)。1H NMR(600MHz,CDCl3):7.44(1H,d,J=16.2Hz),7.29(1H,dd,J=8.4,1.8Hz),7.24(1H,s),7.16(1H,d,J=8.4Hz),6.56(2H,s),6.23(1H,d,J=16.2Hz),6.14(1H,d,J=2.4Hz),5.95(1H,d,J=2.4Hz),5.49(1H,m),4.97(1H,s),2.95(1H,dd,J=17.4,4.8Hz),2.87(1H,dd,J=17.4,3.6Hz),2.26(6H,s),0.86-0.97(45H,m),0.04-0.21(30H,m)。Weigh
化合物6d的合成:Synthesis of
称取化合物4b(370.0mg,0.42mmol)于100mL圆底烧瓶中,加入2.0mL干燥的吡啶,5.0mL干燥的二氯甲烷,在冰浴条件下缓慢滴加含有化合物5b(1.5mmol)的干燥二氯甲烷7.0mL。室温反应过夜,加适量的水和等体积的二氯甲烷萃取三次,二氯甲烷层用无水硫酸钠干燥后浓缩,经硅胶柱层析以石油醚:乙酸乙酯=50:1进行洗脱后得到化合物4”-O-乙酰基-5,7,3’,4’,5’-O-五叔丁基二甲基硅基-表没食子儿茶素反式香豆酸酯(6d,280.0mg,油状,收率62%)。1H NMR(600MHz,CDCl3):7.48(1H,d,J=16.2Hz),7.43(2H,d,J=9.0Hz),7.07(2H,d,J=8.4Hz),6.57(2H,s),6.24(1H,d,J=15.6Hz),6.15(1H,d,J=1.8Hz),5.96(1H,d,J=2.4Hz),5.50(1H,m),4.97(1H,s),2.95(1H,dd,J=17.4,4.8Hz),2.88(1H,dd,J=17.4,3.0Hz),2.28(3H,s),0.86-0.97(45H,m),0.04-0.20(30H,m)。Weigh
化合物7a合成:
称取化合物6b(163.0mg,0.17mmol)于25mL圆底烧瓶中,加入氟氢化钾(136.0mg,1.7mmol),再加入6.0mL干燥的甲醇,室温下反应3.5小时。待反应结束后加入适量的水,用等体积的乙酸乙酯萃取三次。乙酸乙酯层用无水硫酸钠干燥后浓缩,经硅胶柱层析以石油醚:乙酸乙酯=1:1进行洗脱后得到化合物4”-O-乙酰基-表儿茶素反式香豆酸酯(7a,70.9mg,白色粉末,收率85%)。1H NMR(600MHz,DMSO-d6):9.27(1H,s),9.01(1H,s),8.82(1H,s),8.77(1H,s),7.73(2H,d,J=8.4Hz),7.51(1H,dd,J=16.2Hz),7.15(2H,d,J=8.4Hz),6.89(1H,d,J=1.8Hz),6.71(1H,dd,J=8.4,1.8Hz),6.67(1H,d,J=8.4Hz),6.48(1H,d,J=16.2Hz),5.94(1H,d,J=1.8Hz),5.81(1H,d,J=1.8Hz),5.36(1H,br s),5.02(1H,s),2.95(1H,dd,J=17.4,4.8Hz),2.68(1H,br d,J=16.8Hz),2.27(3H,s)。Weigh
化合物7b合成:
称取化合物6d(130.0mg,0.12mmol)于25mL圆底烧瓶中,加入氟氢化钾(476.0mg,6.1mmol),再加入8.0mL干燥的甲醇,50℃下反应6小时。反应产物浓缩后经LH-20凝胶柱层析,以甲醇洗脱后得到化合物4”-O-乙酰基-表没食子儿茶素反式香豆酸酯(7b,36.0mg,白色粉末,收率60%)。1H NMR(600MHz,DMSO-d6):9.29(1H,s),9.03(1H,s),8.76(1H,s),8.00(1H,s),7.72(2H,d,J=8.4Hz),7.51(1H,dd,J=16.2Hz),7.15(2H,d,J=9.0Hz),6.46(1H,d,J=16.2Hz),6.40(2H,s),5.94(1H,d,J=2.4Hz),5.79(1H,d,J=2.4Hz),5.34(1H,brs),4.95(1H,s),2.94(1H,dd,J=17.4,4.8Hz),2.67(1H,br d,J=16.2Hz),2.26(3H,s)。Weigh
化合物8a合成:Synthesis of
称取6a(164.0mg,0.16mmol)于25mL圆底烧瓶中,加入氟氢化钾(28.0mg,1.64mmol),再加入6.0mL干燥的甲醇,50℃下反应6小时。反应产物经LH-20凝胶柱层析,以甲醇洗脱后得到化合物表儿茶素反式咖啡酸酯(8a,52.0mg,白色粉末,收率70%)。1H NMR(600MHz,DMSO-d6):7.32(1H,d,J=16.2Hz),6.98(1H,s),6.95(1H,dd,J=6.6,1.8Hz),6.88(1H,s),6.73(1H,d,J=7.8Hz),6.70(1H,dd,J=8.4,1.2Hz),6.67(1H,dd,J=7.8Hz),6.12(1H,d,J=15.6Hz),5.94(1H,d,J=1.8Hz),5.81(1H,d,J=1.8Hz),5.31(1H,br s),5.01(1H,s),2.92(1H,dd,J=17.4,4.8Hz),2.67(1H,br d,J=16.2Hz)。HR-ESI-MS(负离子):m/z451.1040[M-H]-。
化合物8b的合成:Synthesis of
称取7a(50.0mg,0.1mmol)于10mL圆底烧瓶中,加醋酸铵(450.0mg,5.8mmol),加入80%甲醇水溶液2.0mL,室温反应5.5小时。反应产物经LH-20凝胶柱层析,以甲醇洗脱后得到化合物表儿茶素反式香豆酸酯(8b,45.6mg,白色粉末,收率88%)。1H NMR(600MHz,DMSO-d6):7.50(2H,d,J=8.4Hz),7.41(1H,d,J=15.6Hz),6.88(1H,d,J=1.8Hz),6.75(2H,d,J=9.0Hz),6.70(1H,dd,J=8.4,1.2Hz),6.67(1H,d,J=7.8Hz),6.24(1H,d,J=15.6Hz),5.93(1H,d,J=1.8Hz),5.80(1H,d,J=1.8Hz),5.32(1H,br s),5.01(1H,s),2.92(1H,dd,J=17.4,4.8Hz),2.66(1H,br d,J=16.2Hz)。HR-ESI-MS(负离子):m/z435.1088[M-H]-。
化合物8c的合成:Synthesis of
称取6c(60.0mg,0.05mmol)于25mL圆底烧瓶中,加入氟氢化钾(200.0mg,2.56mmol),再加入5.0mL干燥的甲醇,50℃下反应6小时。反应产物经LH-20凝胶柱层析,以甲醇洗脱后得到化合物表没食子儿茶素反式咖啡酸酯(8c,15.0mg,白色粉末,收率60%)。1H NMR(600MHz,DMSO-d6):7.33(1H,d,J=16.8Hz),6.98(1H,d,J=1.8Hz),6.96(1H,dd,J=8.4,1.8Hz),6.72(1H,d,J=8.4Hz),6.39(2H,s),6.09(1H,d,J=16.2Hz),5.93(1H,d,J=1.8Hz),5.79(1H,d,J=2.4Hz),5.28(1H,br s),4.93(1H,s),2.90(1H,dd,J=17.4,4.8Hz),2.64(1H,br d,J=16.2Hz)。HR-ESI-MS(负离子):m/z 451.1033[M-H]-。Weigh 6c (60.0 mg, 0.05 mmol) into a 25 mL round bottom flask, add potassium bifluoride (200.0 mg, 2.56 mmol), then add 5.0 mL of dry methanol, and react at 50° C. for 6 hours. The reaction product was subjected to LH-20 gel column chromatography and eluted with methanol to obtain the compound epigallocatechin trans-caffeate (8c, 15.0 mg, white powder, yield 60%). 1 H NMR (600MHz, DMSO-d 6 ): 7.33 (1H, d, J = 16.8Hz), 6.98 (1H, d, J = 1.8Hz), 6.96 (1H, dd, J = 8.4, 1.8Hz), 6.72(1H,d,J=8.4Hz),6.39(2H,s),6.09(1H,d,J=16.2Hz),5.93(1H,d,J=1.8Hz),5.79(1H,d,J = 2.4Hz), 5.28 (1H, br s), 4.93 (1H, s), 2.90 (1H, dd, J = 17.4, 4.8Hz), 2.64 (1H, br d, J = 16.2Hz). HR-ESI-MS (negative ion): m/z 451.1033 [MH] - .
化合物8d的合成:Synthesis of
称取7b(36.0mg,0.07mmol)于10mL圆底烧瓶中,加醋酸铵(460.0mg,6.0mmol),加入80%甲醇水溶液2.0mL,室温反应5小时。反应产物经LH-20凝胶柱层析,以甲醇洗脱后得到化合物表没食子儿茶素反式香豆酸酯(8d,18.1mg,白色粉末,收率55%)。1H NMR(600MHz,DMSO-d6):7.49(2H,d,J=8.4Hz),7.41(1H,d,J=15.6Hz),6.75(2H,d,J=8.4Hz),6.39(2H,s),6.22(1H,d,J=15.6Hz),5.93(1H,d,J=2.4Hz),5.79(1H,d,J=1.8Hz),5.30(1H,br s),4.93(1H,s),2.91(1H,dd,J=17.4,4.8Hz),2.65(1H,br d,J=16.2Hz)。HR-ESI-MS(负离子):m/z467.0979[M-H]-。
实施例2Example 2
将实施例1中制备的表儿茶素反式香豆酸酯、表儿茶素反式咖啡酸酯、表没食子儿茶素反式香豆酸酯与表没食子儿茶素反式咖啡酸酯四种羟基肉桂酰酯型儿茶素进行体外抑制α-葡萄糖苷酶活性实验。The epicatechin trans-coumarate, epicatechin trans-caffeate, epigallocatechin trans-coumarate and epigallocatechin trans-caffeate prepared in Example 1 Four hydroxycinnamoyl catechins were tested for their inhibition of α-glucosidase activity in vitro.
2.1实验材料和试剂2.1 Experimental materials and reagents
阿卡波糖、磷酸钾缓冲液(PPBS,10mM,PH为6.9)、α-葡萄糖苷酶(0.1U·mL-1)、4-硝基苯基-α-D-吡喃葡萄糖苷(pNPG,2.5mM)、二甲基亚砜(DMSO)Acarbose, potassium phosphate buffer (PPBS, 10mM, pH 6.9), α-glucosidase (0.1U·mL -1 ), 4-nitrophenyl-α-D-glucopyranoside (pNPG , 2.5mM), dimethyl sulfoxide (DMSO)
2.2实验方法及结果2.2 Experimental methods and results
在96孔板中加入60μL的α-葡萄糖苷酶溶液,分别加入不同浓度梯度的四种羟基肉桂酰酯型儿茶素60μL,在37℃预孵化10min后,分别添加60μL的pNPG溶液,继续在37℃孵化20min后置于酶标仪(25℃),在波长405nm的可见光下,记录反应液的A值。所有样品均重复3次,记为A样品。用60μL的PPBS代替α-葡萄糖苷酶,记为A空白(重复3次),做空白调零。用60μL的PPBS代替样品溶液,记为A测试。用120μL的PPBS代替样品溶液和α-葡萄糖苷酶,记为A对照(重复3次)。Add 60 μL of α-glucosidase solution to a 96-well plate, add 60 μL of four hydroxycinnamoyl ester catechins with different concentration gradients, and pre-incubate at 37°C for 10 minutes, add 60 μL of pNPG solution respectively, and continue to After incubating at 37°C for 20 minutes, place it in a microplate reader (25°C), and record the A value of the reaction solution under visible light with a wavelength of 405nm. All samples were repeated 3 times, which were recorded as A samples. Replace α-glucosidase with 60 μL of PPBS, record it as A blank (repeat 3 times), and make blank zero adjustment. Replace the sample solution with 60 μL of PPBS, denoted as A test. Replace the sample solution and α-glucosidase with 120 μL of PPBS, and record it as control A (repeat 3 times).
对乙酰胆碱酯酶的酶抑制率按以下公式计算:The enzyme inhibition rate to acetylcholinesterase was calculated according to the following formula:
抑制率(%)=(1-(A样品-A空白)/(A测试-A对照))×100%。Inhibition rate (%)=(1-(A sample-A blank)/(A test-A control))×100%.
以酶的相对活力对抑制剂浓度作图,根据抑制曲线即可计算出四种羟基肉桂酰酯型儿茶素与α-葡萄糖苷酶作用的IC50值。所测得的结果如下表所示:The relative activity of the enzyme was plotted against the concentration of the inhibitor, and the IC 50 value of the four hydroxycinnamoyl catechins interacting with α-glucosidase could be calculated according to the inhibition curve. The measured results are shown in the table below:
注:阳性对照药物——阿卡波糖Note: positive control drug - acarbose
由表中的结果可知,本发明制备的四种羟基肉桂酰酯型儿茶素:表儿茶素反式香豆酸酯、表儿茶素反式咖啡酸酯、表没食子儿茶素反式香豆酸酯与表没食子儿茶素反式咖啡酸酯对α-葡萄糖苷酶均有强的抑制作用,可应用于制备降血糖药物,具有广阔的应用前景。As can be seen from the results in the table, four kinds of hydroxycinnamoyl ester type catechins prepared by the present invention: epicatechin trans coumarate, epicatechin trans caffeate, epigallocatechin trans Both coumarate and epigallocatechin trans-caffeate have a strong inhibitory effect on α-glucosidase, and can be used in the preparation of hypoglycemic drugs and have broad application prospects.
应当理解本文所述的例子和实施方式仅为了说明,并不用于限制本发明,本领域技术人员可根据它做出各种修改或变化,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。It should be understood that the examples and implementations described herein are for illustration only, and are not intended to limit the present invention, and those skilled in the art can make various modifications or changes based on it, and within the spirit and principles of the present invention, any Modifications, equivalent replacements, improvements, etc., should all be included within the protection scope of the present invention.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010056390.XA CN111233810B (en) | 2020-01-18 | 2020-01-18 | Preparation method and application of hydroxycinnamoyl ester type catechin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010056390.XA CN111233810B (en) | 2020-01-18 | 2020-01-18 | Preparation method and application of hydroxycinnamoyl ester type catechin |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111233810A CN111233810A (en) | 2020-06-05 |
CN111233810B true CN111233810B (en) | 2023-03-21 |
Family
ID=70877932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010056390.XA Active CN111233810B (en) | 2020-01-18 | 2020-01-18 | Preparation method and application of hydroxycinnamoyl ester type catechin |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111233810B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7379415B2 (en) * | 2021-06-01 | 2023-11-14 | 花王株式会社 | Method for producing catechin conjugate |
CN113429372B (en) * | 2021-06-21 | 2023-10-13 | 安徽农业大学 | Novel 3C-like protease inhibitor and preparation method and application thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988008256A1 (en) * | 1987-04-28 | 1988-11-03 | University Patents, Inc. | Dihydroflavonol derivatives useful as sweeteners |
JPH0517352A (en) * | 1991-07-03 | 1993-01-26 | Mitsui Norin Kk | Sucrase activity-inhibiting agent |
JP2007231009A (en) * | 2006-02-02 | 2007-09-13 | Nagasaki Prefecture | Composition for inhibiting increase in blood glucose level and food and drink containing the same |
CN101182319A (en) * | 2007-12-05 | 2008-05-21 | 中国海洋大学 | A method for extracting epigallocatechin gallate from tea polyphenols |
JP2009007272A (en) * | 2007-06-27 | 2009-01-15 | Toyama Prefecture | New method for producing 3-o-substituted catechin derivative |
CN101492440A (en) * | 2008-01-24 | 2009-07-29 | 上海新康制药厂 | Separation purification process for main catechin component in tea polyphenol and glycosidase activity |
CN105503807A (en) * | 2016-01-25 | 2016-04-20 | 安徽农业大学 | Catechin derivative named as epicatechin trans caffeic acid ester and preparation method and application thereof |
CN105949162A (en) * | 2016-05-09 | 2016-09-21 | 许爱娥 | Application of coffee acid derivative in treatment of vitiligo |
CN106243077A (en) * | 2016-07-29 | 2016-12-21 | 安徽农业大学 | A kind of catechin-derived thing and the purposes in preparing acetylcholine esterase inhibition activity medicine thereof |
CN108926553A (en) * | 2017-05-26 | 2018-12-04 | 中国海洋大学 | A kind of flavone compound is preparing the application in topoisomerase I inhibitor |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6696484B2 (en) * | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
-
2020
- 2020-01-18 CN CN202010056390.XA patent/CN111233810B/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988008256A1 (en) * | 1987-04-28 | 1988-11-03 | University Patents, Inc. | Dihydroflavonol derivatives useful as sweeteners |
JPH0517352A (en) * | 1991-07-03 | 1993-01-26 | Mitsui Norin Kk | Sucrase activity-inhibiting agent |
JP2007231009A (en) * | 2006-02-02 | 2007-09-13 | Nagasaki Prefecture | Composition for inhibiting increase in blood glucose level and food and drink containing the same |
JP2009007272A (en) * | 2007-06-27 | 2009-01-15 | Toyama Prefecture | New method for producing 3-o-substituted catechin derivative |
CN101182319A (en) * | 2007-12-05 | 2008-05-21 | 中国海洋大学 | A method for extracting epigallocatechin gallate from tea polyphenols |
CN101492440A (en) * | 2008-01-24 | 2009-07-29 | 上海新康制药厂 | Separation purification process for main catechin component in tea polyphenol and glycosidase activity |
CN105503807A (en) * | 2016-01-25 | 2016-04-20 | 安徽农业大学 | Catechin derivative named as epicatechin trans caffeic acid ester and preparation method and application thereof |
CN105949162A (en) * | 2016-05-09 | 2016-09-21 | 许爱娥 | Application of coffee acid derivative in treatment of vitiligo |
CN106243077A (en) * | 2016-07-29 | 2016-12-21 | 安徽农业大学 | A kind of catechin-derived thing and the purposes in preparing acetylcholine esterase inhibition activity medicine thereof |
CN108926553A (en) * | 2017-05-26 | 2018-12-04 | 中国海洋大学 | A kind of flavone compound is preparing the application in topoisomerase I inhibitor |
Non-Patent Citations (4)
Title |
---|
"Identification and quantification of hydroxycinnamoylated catechins in tea by targeted UPLC-MS using synthesized standards and their potential use in discrimination of tea varieties";Wei Wang et al.;《LWT -FoodScienceandTechnology》;第142卷;第110963号 * |
"Microencapsulation and the Characterization of Polyherbal Formulation (PHF) Rich in Natural Polyphenolic Compounds";Syed Ammar Hussain et al.;《nutrients》;第10卷;第843号 * |
"Synthesis and structureeactivity relationship of 3-O-acylated "(-)-epigallocatechins as 5α-reductase inhibitors;Shu Fu Lin et al.;《European Journal of Medicinal Chemistry》;第45卷;第6068-6076页 * |
"Towards the discovery of drug-like epigallocatechin gallate analogs as Hsp90 inhibitors";Rohit Bhat et al.;《Bioorganic & Medicinal Chemistry Letters》;第24卷;第2263-2266页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111233810A (en) | 2020-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gao et al. | α-Glucosidase inhibition of 6-hydroxyflavones. Part 3: Synthesis and evaluation of 2, 3, 4-trihydroxybenzoyl-containing flavonoid analogs and 6-aminoflavones as α-glucosidase inhibitors | |
Yuan et al. | New maplexins F–I and phenolic glycosides from red maple (Acer rubrum) bark | |
CN101003528B (en) | En-kaurene diterpenoids and derivatives thereof, preparation methods and uses thereof | |
CN111233810B (en) | Preparation method and application of hydroxycinnamoyl ester type catechin | |
CN102079700A (en) | Method for synthesizing novel tetracyclic diterpene compound from stevioside | |
CN101182319A (en) | A method for extracting epigallocatechin gallate from tea polyphenols | |
SU1072805A3 (en) | Process for preparing derivatives of flavan or their salts | |
ITMI20002201A1 (en) | DRUGS FOR DIABETES | |
Takanashi et al. | New benzofurans related to egonol from immature seeds of Styrax obassia | |
Zhou et al. | Synthesis and antitumor activity of scopoletin derivatives | |
CN101966172B (en) | New purpose of caffeic acid and derivatives thereof | |
Shao et al. | Synthesis, characterization, and antiradical activity of 6-hydroxygenistein | |
Joshi et al. | Quinones and other constituents from the roots of Tecomella undulata | |
CN101724008A (en) | Marsdenia tenacissima C21 steroidal glycoside converted product and preparation method and application thereof | |
Kuramochi et al. | Synthesis and structure–activity relationships of dehydroaltenusin derivatives as selective DNA polymerase α inhibitors | |
Yu et al. | Structural optimization of caffeoyl salicylate scaffold as no production inhibitors | |
CN101792478A (en) | Light affinity labelling small molecular probe based on maslinic acid and preparation method thereof | |
CN101966194A (en) | New application of scutellarin and derivatives thereof | |
Thomas et al. | Isolation, structure, and synthesis of hymenoxin, a new flavone from Hymenoxys scaposa | |
JPH02138291A (en) | Measuring method and measuring reagent for novel oligoglucoside derivative alpha- amylase | |
CN102863419A (en) | Flavan3-alcohol acetylate and preparation method and application thereof | |
CN104672191B (en) | Cardiac phenol E1 compound and its preparation method and application | |
CN108125962B (en) | Application of benzo [ d ] aza-quinazoline compound in preparation of drugs for treating lung cancer | |
Toshifumi et al. | Synthesis of N-acetylglucosaminides of unconjugated and conjugated bile acids | |
CN101891730A (en) | Synthesis and Pharmaceutical Application of 7-Alkoxymethyl Hesperetin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |